（以下内容从东吴证券《医药生物行业跟踪周报：三抗药物研发进入快车道，建议关注泽璟制药、三生制药等》研报附件原文摘录）投资要点本周、年初至今A股医药指数涨幅分别为1.3%、2.5%，相对沪深300的超额收益分别为0.2%、3.6%；本周、年初至今H股生物科技指数涨跌幅分别为0.3%、27.8%，相对于恒生科技指数跑赢-1.7%、9.6%；本周A股原料药（+3.8%）、中药（+1.7%）、医疗服务（+...
Source Link（以下内容从东吴证券《医药生物行业跟踪周报：三抗药物研发进入快车道，建议关注泽璟制药、三生制药等》研报附件原文摘录）投资要点本周、年初至今A股医药指数涨幅分别为1.3%、2.5%，相对沪深300的超额收益分别为0.2%、3.6%；本周、年初至今H股生物科技指数涨跌幅分别为0.3%、27.8%，相对于恒生科技指数跑赢-1.7%、9.6%；本周A股原料药（+3.8%）、中药（+1.7%）、医疗服务（+...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.